Melanoma remains the most aggressive and lethal form of skin cancer, characterized by a high mutational burden and complex signaling dysregulation. Over the ...

Appropriate use of immune checkpoint inhibitors and immunotherapy differs in adults with unresectable, metastatic cutaneous ...

Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...

Rare Disease's Koselugo (selumetinib), an oral, selective MEK inhibitor, has been approved in Canada for the treatment of adult patients with neurofibromatosis type 1 (NF1) who have symptomatic, ...

Alexion, AstraZeneca Rare Disease's Koselugo (selumetinib), an oral, selective MEK inhibitor, has been approved in Canada for the treatment of adult patients with neurofibromatosis type 1 (NF1) who ...

Clinical utility may be greatest with careful patient selection, given frailty-associated toxicity and potential endpoint inflation in indolent tumors, warranting larger validation cohorts and ...

Detailed price information for Pasithea Therapeutics Corp (KTTA-Q) from The Globe and Mail including charting and trades.

Gomekli showed an 87% overall response rate in pediatric low-grade glioma with MAPK pathway activation, with a recommended dose of 3 mg/m2 twice daily. Common adverse effects included weight gain, ...

What Is Koselugo, and Why Does It Matter? Koselugo (selumetinib) is an oral medicine that helps slow the growth of certain tumors. The FDA has approved it for adults with neurofibromatosis type 1 (NF1 ...

-- Evidence of Monotherapy Activity: Partial response observed in a MEK-rechallenge 3rd-line melanoma patient with BRAF V600E mutation who remains on trial for more than 11 months -- -- A second ...

The FDA has approved selumetinib (Koselugo, AstraZeneca) for adults with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). Selumetinib, an oral kinase ...

Findings showed the confirmed ORR was 20% in the selumetinib group vs 5% in the placebo group. The Food and Drug Administration (FDA) has approved Koselugo ® (selumetinib) for adults with ...